12.83 USD
▲+1.05+8.91%
盘后 12.81 -0.16%
2026-09-15
市值
$4.09B
市盈率
122.06
EPS
0.10
股息率
—
52 周区间
6.28 – 13.11
成交量
1.08M
Beta
0.60
目标价
19.93
52W 低 6.2852W 高 13.11
价格走势
公司简介
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...